Dronedarone Hydrochloride and Verapamil Extended Release Tablets
Determining the interaction of Dronedarone Hydrochloride and Verapamil Extended Release Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Using dronedarone together with verapamil can increase the blood levels and effects of both medications. This may increase the risk of serious side effects such as irregular heart rhythm, fluid retention, swelling, heart failure, and excessively low blood pressure. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. You should seek immediate medical attention if you experience sudden, unexplained weight gain; swelling of the hands, ankles, or feet; irregular or slow heartbeat; chest pain; or difficulty breathing during treatment with these medications. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:MONITOR: Coadministration of dronedarone and a calcium channel blocker (CCB) may result in increased plasma concentrations of both drugs. Dronedarone and most CCBs are substrates of CYP450 3A4. In addition, dronedarone and certain CCBs such as diltiazem and verapamil are also moderate inhibitors of the isoenzyme, thus competitive and noncompetitive metabolic inhibition may occur. According to the product labeling, dronedarone increased systemic exposure (AUC) to diltiazem, nifedipine and verapamil by 1.4- to 1.5-fold, while diltiazem and verapamil increased dronedarone AUC by approximately 1.4- to 1.7-fold. Pharmacodynamically, CCBs with depressant effects on the sinus and AV nodes (particularly diltiazem, verapamil, and bepridil) could also potentiate dronedarone's effects on cardiac conduction.
MANAGEMENT: Caution is advised if dronedarone is coadministered with a CCB. The dosage of the CCB should start low and increased only after ECG verification of good tolerability. Patients should be advised to promptly report potential symptoms of toxicity such as excessive fatigue; edema or swelling of the lower extremities; sudden, unexplained weight gain; fainting; difficulty breathing; chest pain or tightness; bradycardia; arrhythmia; or hypotension as indicated by dizziness, fainting, or orthostasis.
- "Product Information. Multaq (dronedarone)." sanofi-aventis , Bridgewater, NJ.
Generic Name: dronedarone
Brand name: Multaq
Synonyms: Dronedarone
Generic Name: verapamil
Brand name: Calan, Isoptin SR, Verelan, Isoptin, Calan SR, Isoptin IV, Covera-HS, Verelan PM
Synonyms: Verapamil
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dronedarone Hydrochloride-Verapamil Hydrochloride
- Dronedarone Hydrochloride-Verapamil Hydrochloride PM
- Dronedarone Hydrochloride-Verapamil Immediate-Release Tablets
- Dronedarone Hydrochloride-Verapamil Injection
- Dronedarone Hydrochloride-Verapamil Intravenous
- Dronedarone Hydrochloride-Verapamil Long-Acting Capsules
- Verapamil Extended Release Tablets-Droperidol
- Verapamil Extended Release Tablets-Droperidol Injection
- Verapamil Extended Release Tablets-Drospirenone
- Verapamil Extended Release Tablets-Drospirenone and estradiol
- Verapamil Extended Release Tablets-Drospirenone and ethinyl estradiol
- Verapamil Extended Release Tablets-Drospirenone, ethinyl estradiol, and levomefolate